A Chinese scientist, He Jiankui, who was jailed for three years for creating the world's first gene-edited babies, is now planning to pursue more genetic editing projects. In 2018, He made headlines by announcing that he had successfully edited the genes of twin girls born in China, aiming to protect them from HIV infection. However, his attempt at making history was short-lived as the Chinese government banned genome editing for reproductive purposes and sentenced him to prison.
He has since emerged with a new goal: preventing Alzheimer's disease through germline gene editing - the process of altering human genes passed on from parents to offspring. He believes that this technology holds great promise for improving human health, but also acknowledges its potential risks and challenges.
The scientist says he has established an independent lab in Beijing, where he is working on a gene therapy for boys with Duchenne muscular dystrophy. However, his focus is now shifting towards preventing Alzheimer's disease, which He believes can be achieved through the introduction of a specific genetic mutation found in Icelanders who are immune to the condition.
He has raised $7 million in funding from donations and investors, but notes that more money - around $10 million - will be needed to complete his research and initiate human trials. While some critics have labeled his efforts as a form of eugenics or "designer babies," He argues that this is not the case, emphasizing the need for responsible regulation and open communication about scientific advancements.
He has already begun working on the germline editing process using human cell lines, mice, and monkey embryos, aiming to develop a system capable of performing 12 simultaneous genetic edits. If successful, his research could potentially prevent a range of major diseases - including cancer, cardiovascular disease, HIV, and more - by modifying human genes.
He's not planning to avoid potential run-ins with Chinese authorities, instead choosing transparency and openness as he continues his work. However, some critics argue that this approach may be insufficient in addressing concerns about the ethics and implications of germline editing technologies.
Overall, He Jiankui's plans to prevent Alzheimer's disease through gene editing mark a significant turning point in the ongoing debate over the benefits and risks of genetic engineering technology.
He has since emerged with a new goal: preventing Alzheimer's disease through germline gene editing - the process of altering human genes passed on from parents to offspring. He believes that this technology holds great promise for improving human health, but also acknowledges its potential risks and challenges.
The scientist says he has established an independent lab in Beijing, where he is working on a gene therapy for boys with Duchenne muscular dystrophy. However, his focus is now shifting towards preventing Alzheimer's disease, which He believes can be achieved through the introduction of a specific genetic mutation found in Icelanders who are immune to the condition.
He has raised $7 million in funding from donations and investors, but notes that more money - around $10 million - will be needed to complete his research and initiate human trials. While some critics have labeled his efforts as a form of eugenics or "designer babies," He argues that this is not the case, emphasizing the need for responsible regulation and open communication about scientific advancements.
He has already begun working on the germline editing process using human cell lines, mice, and monkey embryos, aiming to develop a system capable of performing 12 simultaneous genetic edits. If successful, his research could potentially prevent a range of major diseases - including cancer, cardiovascular disease, HIV, and more - by modifying human genes.
He's not planning to avoid potential run-ins with Chinese authorities, instead choosing transparency and openness as he continues his work. However, some critics argue that this approach may be insufficient in addressing concerns about the ethics and implications of germline editing technologies.
Overall, He Jiankui's plans to prevent Alzheimer's disease through gene editing mark a significant turning point in the ongoing debate over the benefits and risks of genetic engineering technology.